
Derek Wallace, Global Dengue Program Head at Takeda Vaccine Business Unit, discusses the recent Phase 2 results showing its vaccine …

The Philippines has announced that it will investigate how more than 730,000 children received a dengue vaccine, despite safety concerns …

As part of Johnson & Johnson’s acquisition of Actelion, it was able to secure a number of ties with the …

It’s no secret that when individuals leave companies within the pharma industry, they tend to pop up at a rival …

Scott Gottlieb, FDA commissioner, was speaking in front of the House Committee on Energy and Commerce, regarding the 21st Century …

New research published in The Lancet has revealed that type 1 diabetes cannot be understood as a “disease of the …

Vir Biotechnology, a developer of treatments that induce protective and therapeutics immune responses, has hired a CSO with a strong …

After analysing six years’ worth of data on its dengue vaccine, Dengvaxia, Sanofi contacted health authorities to tell them that …

Descriptions of treatments as ‘revolutionary’ or ‘ground-breaking’ are ten a penny in the pharmaceutical industry, very rarely do such treatments …

PrimeVigilance is pleased to announce their collaboration with the International Society of Pharmacovigilance (ISoP) on the upcoming seminar, organised by …

Novartis released Phase 3 data on its leading candidate for wet age-related macular degeneration (AMD) drug and it caused a …

The Veeva European Commercial & Medical Summit will begin tomorrow, seeing more than 800 industry leaders convene at the Marriot …

It’s been a rocky year for AstraZeneca, it has scored some major successes yet its year has been marred by …

The UK government’s Autumn Budget struck a gloomy note for the economy, with figures pointing towards low productivity and the …

Researchers, based in the US, have conducted a large-scale collection of publicly available data and found that significant differences can …